Evidence map›Paper›PMID 23934156›Full record

ArticleJournal of dental research2013

Advances in culture and manipulation of human pluripotent stem cells.

X Qian, L G Villa-Diaz, P H Krebsbach

Abstract read
In one paragraph

Article in Journal of dental research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Cardiac regeneration and diabetes.Regenerative medicine research · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

X QianDepartment of Biologic and Materials Sciences, School of Dentistry.
L G Villa-Diaz
P H Krebsbach

Funding

Osteoblast Lineage Progression from Embryonic Stem CellsR01DE016530 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KAARTINEN, VESA M · 2005 to 2016
$3.9M
NIDCR NIH HHS R01 DE016530NIDCR NIH HHS R01DE016530-06
6 · The paper itself

Abstract

Recent advances in the understanding of pluripotent stem cell biology and emerging technologies to reprogram somatic cells to a stem cell-like state are helping bring stem cell therapies for a range of human disorders closer to clinical reality. Human pluripotent stem cells (hPSCs) have become a promising resource for regenerative medicine and research into early development because these cells are able to self-renew indefinitely and are capable of differentiation into specialized cell types of all 3 germ layers and trophoectoderm. Human PSCs include embryonic stem cells (hESCs) derived from the inner cell mass of blastocyst-stage embryos and induced pluripotent stem cells (hiPSCs) generated via the reprogramming of somatic cells by the overexpression of key transcription factors. The application of hiPSCs and the finding that somatic cells can be directly reprogrammed into different cell types will likely have a significant impact on regenerative medicine. However, a major limitation for successful therapeutic application of hPSCs and their derivatives is the potential xenogeneic contamination and instability of current culture conditions. This review summarizes recent advances in hPSC culture and methods to induce controlled lineage differentiation through regulation of cell-signaling pathways and manipulation of gene expression as well as new trends in direct reprogramming of somatic cells.

Indexed as

Cell Culture TechniquesCell DifferentiationCell LineageCell ProliferationEmbryonic Stem CellsGene Expression RegulationGerm LayersGuided Tissue RegenerationHumansPluripotent Stem CellsSignal Transductionfeeder cellsguided tissue regenerationnuclear reprogrammingpolymersregenerative medicine

Identifiers

PMID23934156
PMCPMC4239209

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.